Brainomix extends Series C to £18.8m as Oxford AI imaging spinout pushes into the US
Oxford-based Brainomix has added £4.8 million (approximately $6.5m/€5.5m) to its Series C financing, bringing the total round to £18.8 million ($25.4m/€21.5m) and providing fresh capital to accelerate the US rollout of its AI-powered imaging platforms for stroke and lung fibrosis.
The extension was led by existing investors Parkwalk Advisors, the UK’s largest growth EIS fund manager, and Australian pension fund Hostplus, both of which participated in the £14 million first close in March 2025. The round also brings in a new US-based investor, Modi Ventures.
“This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care,” said Brainomix CEO and co-founder Michalis Papadakis. “With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.”
Clinical evidence and regulatory standing
Brainomix, a spinout from the University of Oxford, has built its commercial position on a body of clinical evidence that is unusual for an AI imaging company at this stage. Its flagship product, Brainomix 360 Stroke, is a fully automated imaging platform designed to support diagnosis and treatment decisions across the acute stroke pathway. The technology, which is endorsed by the UK’s National Institute for Health and Care Excellence (NICE), has been deployed to more than 300 hospitals and used in over 1.5 million patient cases across more than 20 countries.
The company’s strongest clinical claim is that the platform has been associated with a 50% increase in the number of patients receiving mechanical thrombectomy, a procedure that can substantially reduce post-stroke disability. In stroke care, where speed is critical, automated imaging assessment can directly influence whether a patient is transferred for intervention.
Brainomix has also applied its AI imaging expertise to pulmonary fibrosis with its e-Lung platform, which uses CT-derived biomarkers to identify, monitor and predict disease progression. Both platforms have received FDA clearance – the company holds eight clearances for its stroke platform and two for its e-Lung – positioning it for the strong US commercial expansion.
The new financing will fund expanded customer support and product deployment across US hospitals, where Brainomix already has operations.
“Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence,” said Sahir Ali, founder and general partner of Modi Ventures, in the press release. “We are pleased to join as a new investor and look forward to supporting the company as it expands in the U.S. and accelerates adoption of technologies that meaningfully improve patient outcomes.”
